Microencapsulation of probiotics in plant-based matrices offers a sustainable approach to enhance their viability in functional foods. We evaluated the survival of Lacticaseibacillus rhamnosus GG (ATCC 53103) microencapsulated in food-grade pea protein isolate during simulated in vitro gastrointestinal digestion. The standardised INFOGEST static digestion model was used to simulate gastric (pH 2, 5, and 7) and intestinal conditions, and probiotic viability was measured using colony counts and flow cytometry. Non-encapsulated L. rhamnosus GG lost approximately 50% viability during gastric digestion and less than 20% of L. rhamnosus GG remained alive after subsequent intestinal digestion. In contrast, pea protein microcapsules maintained ≥80%–100% viability throughout digestion. Even at higher gastric pH (5–7), microencapsulation provided significantly better survival than free cells. These results demonstrate that pea protein-based microencapsulation of L. rhamnosus GG markedly improves probiotic survival under digestive conditions. This strategy offers promising applications in sustainable, plant-based probiotic fortified foods, where enhanced delivery of these beneficial bacteria is desired.
Probiotic enumeration in foods and beverages remains anchored in culture dependent colony-forming unit (CFU) counts, the regulatory gold standard for label compliance. However, culturability does not fully equate to viability as environmental stresses can convert probiotic cells into a viable but non-culturable (VBNC) state, where they remain metabolically active but undetectable by CFU counts. Microencapsulation can provide a degree of protection to probiotics against stress; nevertheless, this blind spot in quantification forces manufacturers to overdose formulations or risk non-compliance with health benefits claims. Thus, the efficacy of probiotics may be underestimated when evaluation relies solely on CFU, creating a false dichotomy between VBNC and non-viable cells. Culture-independent methods, including flow cytometry quantification of active fluorescent units (AFUs), viability PCR/dPCR, and rRNA-targeted Flow-FISH, can aid closing this gap by detecting metabolically active cells non-detectable by culturing, providing complementary quantification data to CFU counts alone. Understanding the relationship between quantification by culture and culture-independent methods provides a more accurate measure of probiotic dose delivery in functional foods and beverages. This review covers the current understanding of VBNC state, including induction, detection, and resuscitation in probiotics, with emphasis on experimental controls that differentiate true VBNC resuscitation from population growth. Case studies in Lactobacillus and Bifidobacterium illustrate triggers, molecular mechanisms, and methodological advances. Finally, guidance is provided for the development of an integrated quantification approach that reconciles culture-dependent and culture-independent data, ultimately aiming to improve CFU count accuracy through the controlled resuscitation of VBNC cells.
Background: Thermal processing of functional beverages often drives probiotics into a viable but non-culturable (VBNC) state, causing severe underestimation by conventional colony-forming unit (CFU) assays. Objective: To develop and assess an anaerobic, catalase-assisted resuscitation approach that restores culturability of heat-stressed Lacticaseibacillus rhamnosus GG and aligns CFU counts with actual viable populations. Methods: Dairy beverages (95°C, 30 s; 2 × 106 cells/mL, pH 3.9) containing encapsulated L. rhamnosus GG were incubated at 37°C for 16 h in Rogosa/MRS broth supplemented with 50–100 U/mL catalase under anaerobic conditions before plating. Recovery was benchmarked against flow cytometry (active fluorescent units AFU), whereas pH and glucose monitoring confirmed resuscitation rather than growth. Method performance was examined across three production batches (single-laboratory study) and further evaluated in a multilaboratory setting. Results: Direct plating yielded no CFU, whereas flow cytometry detected 6.34 ± 0.04 log10 AFU/g. After resuscitation, CFU recovered to 6.05 ± 0.05 log10/g (CFU/AFU ratio = 0.86 ± 0.03; P = 0.12). Omitting catalase or anaerobiosis reduced recovery by >1.9 log10 CFU/g. CFU restoration occurred without acidification or glucose depletion, confirming true resuscitation. Single-laboratory reproducibility showed CV < 2%; interlaboratory reproducibility was <15% RSD. Application to heat-treated milk (pH 6.85) yielded 1.74 × 106 CFU/g (CV 15.9%, n = 4), supporting method suitability across other dairy beverages. Conclusion: The catalase-assisted, anaerobic resuscitation developed protocol provides a reproducible workflow for probiotic enumeration in heat-treated beverages. The method is compatible with AOAC/ISO standards, addresses underestimation of counts, and supports adoption into quality control (QC) laboratories for accurate probiotic labeling. Highlights: Heat-stressed L. rhamnosus GG cells recovered culturability when incubated with catalase under anaerobic conditions, restoring CFU counts to AFU-equivalent levels and confirming true resuscitation rather than growth.
Probiotics have gained increasing evidence for their roles in health and disease. Microencapsulation can improve the consistency and efficacy of probiotic-fortified foods by enabling safer delivery to target regions of the gastrointestinal tract. We evaluated a probiotic snack bite containing microencapsulated Lacticaseibacillus rhamnosus GG. Twenty-five healthy adults consumed one snack daily for 28 days, then a 7-day washout, followed by crossover. Outcomes included gastrointestinal health analysis, bowel movement ease and frequency, bloating, overall gut comfort, shotgun metagenomics and systemic biomarkers of barrier, brain function and inflammation. Compared with the lower-fibre control snack, the probiotic snack was associated with easier bowel movements and fewer constipation reports at end of period, while bloating remained low in both periods. However, because the products differed in nutritional composition, these findings cannot be attributed to L. rhamnosus GG alone inflammatory and barrier biomarkers did not differ between treatments and stayed within healthy ranges. In an exploratory subgroup with elevated baseline serotonin, end-of-period serotonin was lower after the probiotic-containing snack than after the control snack, whereas brain-derived neurotrophic factor was unchanged. Daily intake of microencapsulated Lacticaseibacillus rhamnosus GG was well tolerated and was associated with exploratory difference in bowel habit and serum serotonin in a subgroup, without detectable changes in systemic inflammation or barrier biomarkers.
Background: n-3 Docosapentaenoic acid (DPA; 22:5 n-3) is increasingly viewed as a distinct long-chain omega-3 fatty acid with biological activities that are not fully captured by EPA or DHA. However, progress remains limited by restricted access to high-purity DPA: most commercial sources contain DPA as a minor component, and published isolation strategies often yield only enriched mixtures or require multi-step workflows that are difficult to scale in standard laboratories. Objectives: To establish a robust, laboratory-accessible purification workflow to obtain DPA ethyl ester at high purity while preserving oxidative quality. Methods: Candidate lipid sources were screened to select an optimal DPA-containing feedstock. Oils were stabilized with antioxidants and pre-fractionated by cold crystallization (−20 °C) to reduce saturated lipids and oxidation by-products. Preparative separation used a stacked C18 flash system (15 μm + 45 μm in series) operated isocratically (methanol/water 92:8, v/v) at 120 mL/min. Fractions were analyzed by GC and iteratively reinjected to progressively enrich the DPA window. Solvent was recovered by distillation and reused. Results: Omegavie® 4020EE (6.6% DPA) was identified as the best starting material. Pretreatment eliminated detectable TBARS-derived malondialdehyde. The isocratic purification-loop strategy produced tens of grams of DPA ethyl ester at >98% purity (GC–FID) with high overall recovery (~90%) and >90% solvent recycling. Identity and purity were confirmed by GC–MS and ^1H NMR, and oxidation indices remained low (peroxide value < 0.2 meq/kg; p-anisidine < 3). Conclusions: This scalable, solvent-conscious protocol enables reliable access to high-purity DPA and should be adaptable to other low-abundance polyunsaturated fatty acids.
Probiotic efficacy may depend on reliable intestinal exposure, yet clinical evidence linking delivery engineering to measurable microbiome responses in humans remains limited. We compared two active doses of microencapsulated Lacticaseibacillus rhamnosus GG in 26 healthy adults in a randomised, double-blind, two-period crossover trial. Participants received 2 × 109 CFU/day (2BN) and 6 × 109 CFU/day (6BN) for 28 days each in a yoghurt drink, separated by a 14-day washout. Gastrointestinal metrics, tolerance, bowel-habit metrics, and the measured biomarkers remained stable across both doses. By metagenomics, L. rhamnosus was detected in stools in 8/23 participants at baseline, 12/23 participants after 6BN, and 10/23 after 2BN. These data represent marginal prevalence counts and does not establish individual acquisition, viability, persistence or colonisation. Species-level PERMANOVA on Aitchison distances showed a significant within-period microbiome shift during 6BN that was not observed during 2BN. There were directional changes in commensal anaerobic taxa and metagenomic functional modules related to vitamin/cofactor biosynthesis, polyamine biosynthesis, glycogen degradation, multidrug-resistance efflux pumps, and tetrahydrobiopterin biosynthesis. Microencapsulated L. rhamnosus GG was safe and well tolerated at both doses.